Treats hypertension. ANDA 76194, held by Watson Laboratories. Hydrochlorothiazide; Lisinopril.
As of Nov 21, 2026, ANDA 76194 (Lisinopril and Hydrochlorothiazide), held by Watson Laboratories, was first approved by FDA on Jul 1, 2002, with 11 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lisinopril and Hydrochlorothiazide Tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2002 | Original application | Approved | None posted |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide25MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Jul 7, 2020 | Supplement 35Labeling · Standard review | Approved | None posted |
| Jul 7, 2020 | Supplement 37Labeling · Standard review | Approved | None posted |
| Jul 7, 2020 | Supplement 38Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 34Labeling · Standard review | Approved | None posted |
| Sep 10, 2013 | Supplement 31Labeling · Standard review | Approved | None posted |
| Sep 10, 2013 | Supplement 32Labeling · Standard review | Approved | None posted |
| Sep 10, 2013 | Supplement 33Labeling · Standard review | Approved | None posted |
| Jul 31, 2008 | Supplement 16Labeling | Approved | None posted |
| Jan 29, 2008 | Supplement 13Labeling | Approved | None posted |
| Jan 10, 2007 | Supplement 10Labeling | Approved | None posted |
| Aug 17, 2004 | Supplement 5Labeling | Approved | None posted |
| Jul 1, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters